Sarcomas

PM1183-C-010-22

Phase IIb/III, randomized, controlled, open-label study to evaluate lurbinectedin in combination with;doxorubicin versus doxorubicin monotherapy as first-line treatment in patients;suffering from metastatic leiomyosarcoma.

Open at Paris since : 24/05/2024
Target : Adult
Phase : Phase II/III

Trial description

Determine whether lurbinectedin;combination with doxorubicin as treatment for;first line in patients with LMS;metastatic prolongs the period during which the disease;does not worsen (progression-free survival, PFS), compared to;doxorubicin monotherapy.

Url of the trial

Main investigator

SARAH WATSON

Médecin

Contact